Physician profile
Raja Mudad
NPI 1427068154
$422,305.01
in general payments reported to CMS, 2019-2025
65 companies · $21K in 2025
The $21K reported for 2025 was more than what 93% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $67K · 2021: $115K · 2022: $135K · 2023: $28K · 2024: $14K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $48K · Travel and Lodging: $6,496 · Food and Beverage: $6,000 · Honoraria: $2,025 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $47,699.60 |
| Travel and Lodging | $6,496.29 |
| Food and Beverage | $5,999.91 |
| Honoraria | $2,025.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,370.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $95,928.94 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Regeneron Healthcare Solutions, INC. | $78,575.03 | 2021-2025 | Libtayo |
| Astrazeneca Pharmaceuticals Lp | $77,120.40 | 2019-2025 | Imfinzi, Tagrisso, Enhertu |
| Lilly USA, LLC | $44,228.03 | 2019-2024 | Retevmo, Jaypirca |
| Blueprint Medicines Corporation | $35,431.25 | 2020-2022 | |
| Regeneron Pharmaceuticals, INC. | $17,433.31 | 2022-2023 | Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14,159.15 | 2019-2021 | |
| Daiichi Sankyo INC. | $10,270.66 | 2019-2025 | Enhertu, Enhertu, Datroway |
| Genentech USA, INC. | $10,026.38 | 2019-2025 | Tecentriq |
| Novartis Pharmaceuticals Corporation | $8,047.59 | 2019-2025 | Tabrecta |
| Coherus Oncology, INC. | $7,173.74 | 2022-2024 | |
| Abbvie INC. | $4,085.95 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $3,716.63 | 2019-2025 | Alunbrig |
| Tesaro, INC. | $3,453.99 | 2019 | |
| Janssen Biotech, INC. | $2,724.80 | 2019-2025 | Rybrevant, Carvykti, Erleada |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raja Mudad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.